Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.

Lou, Emil; Vogel, Rachel I; Hoostal, Spencer; Klein, Molly; Linden, Michael A; Teoh, Deanna; Geller, Melissa A · JAMA Oncol · 2019

Where this comes from

Record sourced from PubMed, PMID 31152668.
Also identified by DOI 10.1001/jamaoncol.2019.1943 and PMC identifier 6547254.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

This study assesses tumor-stroma proportion and compares this finding with the development of resistance to platinum-based chemotherapy in women newly diagnosed with ovarian carcinoma.

Read the full text

View on PubMed · Publisher (DOI)